Sanofi invests in the future of mRNA with plan to pump billions of dollars into next-gen cell therapy business
With Moderna and Pfizer/BioNTech paving the road for mRNA therapeutics, a gold rush is underway across biopharma to take that promising baton and run with it into new disease areas. Now, Sanofi is engineering an ambitious — and expensive —plan to retool its R&D approach around mRNA vaccines, and it’s leaning on a major research pact to help get it there.
Sanofi will invest up to $477 million per year to build out its “end-to-end” internal capabilities in mRNA, the cell therapy technology underpinning Moderna and Pfizer/BioNTech’s Covid-19 vaccines with red-hot potential in other diseases, the French drugmaker said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.